ABSTRACT
SAR about the B-ring of a series of N(2)-aroyl anthranilamide factor Xa (fXa) inhibitors is described. B-ring o-aminoalkylether and B-ring p-amine probes of the S1' and S4 sites, respectively, afforded picomolar fXa inhibitors that performed well in in vitro anticoagulation assays.
Subject(s)
Antithrombin III/chemical synthesis , Factor Xa Inhibitors , Fluorescent Dyes/pharmacology , ortho-Aminobenzoates/pharmacology , Anticoagulants/chemistry , Antithrombin III/chemistry , Binding Sites , Chemistry, Pharmaceutical/methods , Dose-Response Relationship, Drug , Drug Design , Drug Evaluation, Preclinical , Fluorescent Dyes/chemical synthesis , Humans , Kinetics , Models, Chemical , Molecular Conformation , Structure-Activity Relationship , ortho-Aminobenzoates/chemical synthesisABSTRACT
Several non-amidino S1 derivatives of the 1,2-diaminobenzene-based scaffold (4) were synthesized and evaluated for their ability to bind to the active site and inhibit the human protease factor Xa. A subset of these compounds were also evaluated for their anticoagulant effects in human plasma as measured by prothrombin time (PT).
Subject(s)
Anticoagulants/chemical synthesis , Benzene Derivatives/chemical synthesis , Factor Xa Inhibitors , Anticoagulants/pharmacology , Benzene Derivatives/pharmacology , Binding Sites , Blood Coagulation/drug effects , Factor Xa/metabolism , Humans , Models, Molecular , Protease Inhibitors/chemical synthesis , Protease Inhibitors/pharmacology , Protein Binding , Prothrombin Time , Structure-Activity RelationshipABSTRACT
Pyrazole-based inhibitors of the transforming growth factor-beta type I receptor kinase domain (TbetaR-I) are described. Examination of the SAR in both enzyme- and cell-based in vitro assays resulted in the emergence of two subseries featuring differing selectivity versus p38 MAP kinase. A common binding mode at the active site has been established by successful cocrystallization and X-ray analysis of potent inhibitors with the TbetaR-I receptor kinase domain.